Abivax Announces Availability of Preparatory Documents for 2026 Annual General Meeting
Abivax SA (ABVX) has announced the availability of preparatory documents for its upcoming Annual Ordinary and Extraordinary General Meeting, scheduled for May 11, 2026, in Paris, France. The company, which is currently focused on developing its lead drug candidate, obefazimod (ABX464), for the treatment of ulcerative colitis, published the preliminary notice of the meeting including the agenda and draft resolutions in the Bulletin des Annonces LΓ©gales Obligatoires (BALO) on April 3, 2026. These documents, which provide instructions on how shareholders can attend and vote, are now accessible via the company's website in compliance with French commercial law. This filing is primarily administrative in nature, serving to inform shareholders of the logistical details and regulatory filings associated with the annual meeting. No updates regarding clinical trial data or corporate strategy were disclosed in this specific announcement.